Company intelligence / Profile preview

Jiangsu Pacific Meinuoke Bio Pharmaceutical Co., Ltd.

Changzhou, Jiangsu, Chinapacificmeinuoke.com ↗

Ownership: Private
Employees: ~250
Development stage: Commercial

Overview

The company has multiple programs in development, with Meplazumab being their most advanced candidate currently in Phase 2/3 for COVID-19 and Phase 2 for Malaria. Their CAR-T therapies are in Phase 1/2 for various cancers.

Therapeutic areas: OncologyImmunologyNeurologyInfectious Diseases
Modalities: Monoclonal antibodiesCell therapyBiosimilars
Industry: Biotech

Drug pipeline

1 asset

meplazumab

Beyond the preview

Go deeper on Jiangsu Pacific Meinuoke Bio Pharmaceutical Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jiangsu Pacific Meinuoke Bio Pharmaceutical Co., Ltd..

Explore the full profile